Exagen Inc (XGN) Stock Price, Quote & News

Company Profile

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative o...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 760 560 1501

Website: www.exagen.com

Address:

1261 Liberty Way, Suite C, Vista, United States

totumfaktum88 Jan. 30 at 3:15 PM

$XGN I’m wondering, what if someone just want buy the company with a discount price? This kind of agressive control just unusual. The RSI is continuesly oversold for 2 month now. IMO it will fall to $2.5. Other idea, someone just want to bleed out the company.

0 · Reply

totumfaktum88 Jan. 27 at 3:29 PM

$XGN They are forcing the price to 52 week low or lower without question but without any reasonable choice. "Punch the kid if he let it." Turn your seatbelts and welcome the 3s and 2s.

0 · Reply

totumfaktum88 Jan. 26 at 4:18 PM

$XGN Canaccord reiterated their price target ($15 ) with a buy btw.

0 · Reply

totumfaktum88 Jan. 26 at 2:37 PM

$XGN In short: everyone say good about it, but a +20% q4 and yoy earning wasnt enough. MMs waiting for the q4 meeting, meanwhile they are letting fall like a knife.

1 · Reply

StockHawkZero Jan. 24 at 8:03 AM

$XGN Looking to reenter into this gem after 1 year absence. Need to reevaluate the company to gauge the entry price. Anyone can point to a good post on the topic as a starting point?

0 · Reply

PLATINUM_TRADES Jan. 22 at 3:24 PM

$XGN Sorry I meant today 😊😊👇👇

2 · Reply

PLATINUM_TRADES Jan. 21 at 8:12 PM

$XGN Pow!! Just like that my team is making duckets! I told u when I added👇👇.. $5.00 Today?? 🤔

0 · Reply

PLATINUM_TRADES Jan. 21 at 2:49 PM

$XGN Adds! I got time.. Patience 🥩 🥩

0 · Reply

PLATINUM_TRADES Jan. 21 at 1:07 PM

$XGN Another beat down stock ended good yesterday should make a move towards $5.00 today imo on this bounce🚨🚨

0 · Reply

totumfaktum88 Jan. 15 at 3:27 PM

$XGN It’s time to buy.

0 · Reply

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Nov 11, 2025, 9:00 AM EST - 2 months ago

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Nov 4, 2025, 3:56 PM EST - 3 months ago

Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 3 months ago

Exagen Inc. Reports Strong Q3 2025 Results

Oct 23, 2025, 9:15 AM EDT - 3 months ago

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Oct 21, 2025, 4:05 PM EDT - 3 months ago

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Exagen Inc. to Participate in Third Quarter Investor Conferences

Jul 29, 2025, 3:09 PM EDT - 6 months ago

Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 8:00 AM EDT - 6 months ago

Exagen Inc. Reports Strong Q2 2025 Results

Jul 17, 2025, 4:05 PM EDT - 7 months ago

Exagen Inc. Appoints Chas McKhann to Board of Directors

Jul 15, 2025, 4:05 PM EDT - 7 months ago

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

Jun 23, 2025, 9:00 AM EDT - 7 months ago

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

May 9, 2025, 4:05 PM EDT - 9 months ago

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

May 8, 2025, 8:30 AM EDT - 9 months ago

Exagen Inc. Prices Public Offering of Common Stock

May 7, 2025, 4:05 PM EDT - 9 months ago

Exagen Inc. Announces Proposed Public Offering of Common Stock

May 5, 2025, 4:51 PM EDT - 9 months ago

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

May 5, 2025, 8:00 AM EDT - 9 months ago

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

Apr 28, 2025, 9:00 AM EDT - 9 months ago

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

Apr 26, 2025, 3:31 AM EDT - 10 months ago

Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability

Apr 21, 2025, 4:05 PM EDT - 10 months ago

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

Mar 11, 2025, 1:13 PM EDT - 11 months ago

Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 8:00 AM EDT - 11 months ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Feb 25, 2025, 4:05 PM EST - 1 year ago

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

Feb 4, 2025, 4:05 PM EST - 1 year ago

Exagen Inc. to Participate in Upcoming Investor Conferences

Jan 12, 2025, 12:00 PM EST - 1 year ago

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Dec 12, 2024, 9:00 AM EST - 1 year ago

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Nov 14, 2024, 4:30 PM EST - 1 year ago

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Nov 12, 2024, 1:09 PM EST - 1 year ago

Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript

Oct 21, 2024, 4:05 PM EDT - 1 year ago

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

Aug 5, 2024, 10:49 AM EDT - 1 year ago

Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 9:00 AM EDT - 1 year ago

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

Jul 22, 2024, 9:00 AM EDT - 1 year ago

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

Jun 10, 2024, 1:14 PM EDT - 1 year ago

Time to Play 5 Top-Ranked Stocks With Rising P/E?

AMC BNBX HCAT YOU

May 13, 2024, 11:25 AM EDT - 1 year ago

Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript

May 13, 2024, 8:00 AM EDT - 1 year ago

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Exagen to Announce First Quarter 2024 Results on May 13, 2024

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Exagen Inc. Announces Changes to the Board of Directors

Mar 18, 2024, 1:23 PM EDT - 2 years ago

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

Mar 8, 2024, 9:00 AM EST - 2 years ago

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 7, 2024, 4:05 PM EST - 2 years ago

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Jan 7, 2024, 12:00 PM EST - 2 years ago

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Nov 20, 2023, 8:37 AM EST - 2 years ago

Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 2 years ago

Exagen Inc. Reports Strong Third Quarter 2023 Results

Nov 9, 2023, 4:05 PM EST - 2 years ago

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

Oct 30, 2023, 4:05 PM EDT - 2 years ago

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

Sep 28, 2023, 4:05 PM EDT - 2 years ago

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

Sep 12, 2023, 4:05 PM EDT - 2 years ago

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

totumfaktum88 Jan. 30 at 3:15 PM

0 · Reply

totumfaktum88 Jan. 27 at 3:29 PM

$XGN They are forcing the price to 52 week low or lower without question but without any reasonable choice. "Punch the kid if he let it." Turn your seatbelts and welcome the 3s and 2s.

0 · Reply

totumfaktum88 Jan. 26 at 4:18 PM

$XGN Canaccord reiterated their price target ($15 ) with a buy btw.

0 · Reply

totumfaktum88 Jan. 26 at 2:37 PM

$XGN In short: everyone say good about it, but a +20% q4 and yoy earning wasnt enough. MMs waiting for the q4 meeting, meanwhile they are letting fall like a knife.

1 · Reply

StockHawkZero Jan. 24 at 8:03 AM

$XGN Looking to reenter into this gem after 1 year absence. Need to reevaluate the company to gauge the entry price. Anyone can point to a good post on the topic as a starting point?

0 · Reply

PLATINUM_TRADES Jan. 22 at 3:24 PM

$XGN Sorry I meant today 😊😊👇👇

2 · Reply

PLATINUM_TRADES Jan. 21 at 8:12 PM

$XGN Pow!! Just like that my team is making duckets! I told u when I added👇👇.. $5.00 Today?? 🤔

0 · Reply

PLATINUM_TRADES Jan. 21 at 2:49 PM

$XGN Adds! I got time.. Patience 🥩 🥩

0 · Reply

PLATINUM_TRADES Jan. 21 at 1:07 PM

$XGN Another beat down stock ended good yesterday should make a move towards $5.00 today imo on this bounce🚨🚨

0 · Reply

totumfaktum88 Jan. 15 at 3:27 PM

$XGN It’s time to buy.

0 · Reply

garygb Jan. 14 at 7:12 PM

$XGN Analysts love this one. Adding on.

0 · Reply

totumfaktum88 Jan. 14 at 6:44 PM

$XGN Gap filled agressively.

1 · Reply

totumfaktum88 Jan. 13 at 9:16 PM

$XGN Gap is close to be filled.

0 · Reply

totumfaktum88 Jan. 13 at 8:19 PM

$XGN what a nice slow bloodbath. Like a small blood waterfall. Any news about that? Is the “Sell the news” caused this?

0 · Reply

totumfaktum88 Jan. 13 at 2:52 PM

$XGN shame

0 · Reply

briefingcom Jan. 12 at 1:13 PM

$XGN: Exagen (+4.8%) sees Q4 revs in-line https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260112051045XGN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

DataPrivacyD6 Dec. 26 at 4:51 PM

$XGN Long-term holders appear to prioritize operational credibility. Balance sheet resilience remains an underappreciated swing factor. Confidence weakens if progress becomes episodic rather than consistent. Upside remains tied to tangible progress, not assumptions.

0 · Reply

SuperGreenToday Dec. 20 at 2:51 AM

$XGN Share Price: $6.43 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.36 – $1.67 Potential Upside: 68% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

IN0V8 Nov. 10 at 5:25 PM

$XGN BTIG raises target price to $15 from $13

0 · Reply

JarvisFlow Nov. 10 at 11:51 AM

BTIG updates rating for Exagen ( $XGN ) to Buy, target set at 13 → 15.

0 · Reply

JarvisFlow Nov. 5 at 5:27 PM

B. Riley Securities has updated their rating for Exagen ( $XGN ) to Buy with a price target of 18.

0 · Reply

JarvisFlow Oct. 22 at 12:10 PM

BTIG has adjusted their stance on Exagen ( $XGN ), setting the rating to Buy with a target price of 11 → 13.

0 · Reply

Market Cap	89.52M
Revenue (ttm)	55.64M
Net Income (ttm)	-15.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27.17%
Debt to Equity Ratio	1.26

Volume	1,357,900
Avg Vol	449,176
Day's Range	N/A - N/A
Shares Out	22.66M
Stochastic %K	10%
Beta	1.86
Analysts	Strong Sell
Price Target	$14.71